Modulation of multidrug resistance by SDZ PSC 833 in leukemic and solid-tumor-bearing mouse models

Japanese Journal of Cancer Research

Volumn 87, Issue 2, 1996, Pages 184-193

  Watanabe, Toru ^a,c   Naito, Mikihiko ^b   Oh hara, Tomoko ^a   Itoh, Yohjiro ^c   Cohen, Dalia ^d   Tsuruo, Takashi ^a,b  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Sandoz Pharmaceuticals Ltd   (Japan)

^d Sandoz Pharma Ltd   (Switzerland)

Author keywords

Colon adenocarcinoma 26; Cyclosporin A; Human colorectal adenocarcinoma HCT 15; P glycoprotein; P388 leukemia

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOSPORIN DERIVATIVE; DOXORUBICIN; ETOPOSIDE; GLYCOPROTEIN P; IMMUNOSUPPRESSIVE AGENT; VALSPODAR; VINCRISTINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER MODEL; COLON ADENOCARCINOMA; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LEUKEMIA P 388; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; SOLID TUMOR;

EID: 0029920496     PISSN: 09105050     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1349-7006.1996.tb03157.x     Document Type: Article

References (24)

1. Tsuruo, T. Mechanism of multidrug resistance and implications for therapy. Jpn. J. Cancer Res., 79, 285-296 (1988).
2. Chin, K.-V., Pastan, I. and Gottesman, M. M. Function and regulation of the human multidrug resistance gene. Adv. Cancer Res., 60, 157-180 (1993).
3. Tsuruo, T. Reversal of multidrug resistance by calcium channel blockers and other agents. In "Molecular and Cellular Biology of Multidrug Resistance in Tumor Cells," ed. I. B. Roninson, pp. 349-372 (1991). Plenum Press, New York.
4. Ford, J. M. and Hait, W. N. Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol. Rev., 42, 155-199 (1990).
5. Tsuruo, T., Iida, H., Tsukagoshi, S. and Sakurai, Y. Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. Cancer Res., 41, 1967-1972 (1981).
6. Naito, M., Oh-hara, T., Yamazaki, A., Danki, T. and Tsuruo, T. Reversal of multidrug resistance by an immunosuppressive agent FK-506. Cancer Chemother. Pharmacol., 29, 195-200 (1992).
7. Shinoda, H., Inaba, M. and Tsuruo, T. In vivo circumvention of vincristine resistance in mice with P388 leukemia using a novel compound, AHC-52. Cancer Res., 49, 1722-1726 (1989).
8. Cros, S., Guilbaud, N., Berlion, M., Dunn, T., Regnier, G., Dhainaut, A., Atassi, G. and Bizzari, J.-P. In vivo evidence of complete circumvention of vincristine resistance by a new triazinoaminopiperidine derivative S 9788 in P388/VCR leukemia model. Cancer Chemother. Pharmacol., 30, 491-194 (1992).
9. Sato, W., Fukuzawa, N., Nakanishi, O., Baba, M., Suzuki, T., Yano, O., Naito, M. and Tsuruo, T. Reversal of multidrug resistance by a novel quinoline derivative, MS-209. Cancer Chemother. Pharmacol., 35, 271-277 (1995).
10. Boesch, D., Gaveriaux, C., Jachez, B., Pourtier-Manzanedo, A., Bollinger, P. and Loor, F. In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833. Cancer Res., 51, 4226-4233 (1991).
11. Watanabe, T., Tsuge, H., Oh-hara, T., Naito, M. and Tsuruo, T. Comparative study on reversal efficacy of SDZ PSC 833, cyclosporine A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol., 34, 235-241 (1995).
12. Sikic, B. I. Modulation of multidrug resistance: at the threshold. J. Clin. Oncol., 11, 1629-1635 (1993).
13. Corbett, T. H., Valeriote, F. A. and Baker, L. H. Is the P388 murine tumor no longer adequate as a drug discovery model? Invest. New Drugs, 5, 3-20 (1987).
14. Iwahashi, T., Okouchi, E., Ariyoshi, K., Watabe, H., Amann, E., Mori, S., Tsuruo, T. and Ono, K. Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in the nude mouse model. Cancer Res., 53, 5475-5482 (1993).
15. Geran, R. I., Greenberg, N. R., Macdonald, M. M., Schumacher, A. M. and Abbott, B. J. Protocols for screening chemical agents and natural products against animal tumors and other biological systems (third edition). Cancer Chemother. Rep., 3, 1-103 (1972).
16. Bissery, M.-C., Guenard, D., Gueritte-Voegelein, F. and Lavelle, F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res., 51, 4845-4852 (1991).
17. Keller, R. P., Altermatt, H. J., Nooter, K., Poschmann, G., Laissue, J. A., Bollinger, P. and Hiestand, P. C. SDZ PSC 833, a non-immunosuppressive cyclosporine: its potency in overcoming P-glycoprotein-mediated multidrug resistance of murine leukemia. Int. J. Cancer, 50, 593-597 (1992).
18. Kraus-Berthier, L., Guilbaud, N., Peglion, J.-L., Leonce, S., Lombet, A., Pierre, A. and Atassi, G. In vivo reversal of multidrug resistance by two new dihydropyridine derivatives S16317 and S16324. Acta Oncol., 33, 631-637 (1994).
19. Tsuruo, T., Iida, H., Tsukagoshi, S. and Sakurai, Y. Cure of mice bearing P388 leukemia by vincristine in combination with a calcium channel blocker. Cancer Treat. Rep., 69, 523-525 (1985).
20. Dong, J., Naito, M., Tatsuta, T., Seimiya, H., Johdo, O. and Tsuruo, T. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines. Oncol. Res., 7, 245-252 (1995).
21. Keller, R. P., Altermatt, H. J., Donatsch, P., Zihlmann, H., Laissue, J. A. and Hiestand, P. C. Pharmacologic interactions between the resistance-modifying cyclosporine SDZ PSC 833 and etoposide (VP 16-213) enhance in vivo cytostatic activity and toxicity. Int. J. Cancer, 51, 433-438 (1992).
22. Gonzalez, O., Colombo, T., Imperatori, L., Zucchetti, M., de Fusco, M. and D'Incalci, M. Effects of cyclosporine SDZ-PSC 833 (PSC 833) on the pharmacokinetics and toxicity of doxorubicin in mice. Anti-Cancer Drugs, (Suppl. 1) 5, 22 (1994).
23. Tsuruo, T., Oh-hara, T., Iida, H., Tsukagoshi, S., Sato, Z., Matsuda, I., Iwasaki, S., Okuda, S., Shimizu, F., Sasagawa, K., Fukami, M., Fukuda, K. and Arakawa, M. Rhizoxin, a macrocyclic Iactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines. Cancer Res., 46, 381-385 (1986).
24. Tsuruo, T., Yusa, K., Sudo, Y., Takahashi, R. and Sugimoto, Y. A fluorine-containing anthracycline (ME2303) as a new antitumor agent against murine and human tumors and their multidrug-resistant sublines. Cancer Res., 49, 5537-5542 (1989).